Chronic Pain News and Research

RSS

HealthSaaS enters innovative alliance with iMPak for chronic pain management and medication adherence

The iMPak Health Journal for Pain empowers patients to easily record their pain levels before and after their prescribed medication regimen, providing physicians with readily available, useful, patient information.

11 Jan 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo Pharmaceuticals announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine.

6 Jan 2012

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

BioDelivery Sciences International, Inc. today announced the signing of a worldwide license and development agreement with Endo Pharmaceuticals for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain.

6 Jan 2012

Arcion receives U.S. patent allowance for ARC-2022 to treat PHN

Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022.

5 Jan 2012

Ampio completes enrollment phase of Australian Ampion In Knee trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that it is has completed the expanded patient enrollment phase of its Ampion In Knee (AIK) trials in Australia.

3 Jan 2012

Viewpoints: Picking the 'right fights'; Sebelius's 'special place' in history

Republicans do need to fight for their priorities, but it helps to pick the right fights. They should return in 2012 ready to make their differences clear on taxes, health care, regulation, and how to grow an economy (12/23).

23 Dec 2011

Study measures brain activity in infants to better understand their pain response

Recently, the accuracy of current methods of pain assessment in babies have been called into question. New research from London-area hospitals and the University of Oxford measures brain activity in infants to better understand their pain response.

22 Dec 2011

Actavis enters LOI with QRxPharma to commercialize MoxDuo IR in the U.S.

Actavis Group, the international generic pharmaceuticals company, today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited to commercialize MoxDuo IR in the United States.

21 Dec 2011

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Nektar Therapeutics today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in healthy subjects.

14 Dec 2011

Link between vitamin D deficiency and urinary incontinence

Vitamin D deficiency is higher among certain demographic segments, including women, the elderly, and the obese. All three groups also share an increased risk of pelvic floor problems, including urinary incontinence. Could there be a connection? Perhaps so, according to recent research.

12 Dec 2011

Girls suffer more frequently from chronic pain than boys

Children who suffer from persistent or recurring chronic pain may miss school, withdraw from social activities, and are at risk of developing internalizing symptoms such as anxiety, in response to their pain. In the first comprehensive review of chronic pain in children and adolescents in 20 years, a group of researchers found that more children now are suffering from chronic pain and that girls suffer more frequently from chronic pain than boys.

9 Dec 2011

FDA approves Boston Scientific's Infinion 16 Lead for chronic pain management

Boston Scientific Corporation announces U.S. Food and Drug Administration (FDA) approval of the Infinion 16 Percutaneous Lead for its Precision Plus Spinal Cord Stimulator (SCS) System, the first rechargeable SCS device for chronic pain management.

9 Dec 2011

Combination of cannabinoids and opiates could help reduce chronic pain

A UCSF study suggests patients with chronic pain may experience greater relief if their doctors add cannabinoids - the main ingredient in cannabis or medical marijuana - to an opiates-only treatment. The findings, from a small-scale study, also suggest that a combined therapy could result in reduced opiate dosages.

7 Dec 2011

Biologists discover how fruit flies can provide solutions to human pain, control insect-borne diseases

Studies of a protein that fruit flies use to sense heat and chemicals may someday provide solutions to human pain and the control of disease-spreading mosquitoes.

7 Dec 2011

Chronic pain affects marital communication and ability to cope

Chronic pain suffered by one spouse can affect marital communication and influence the partner's ability to cope with a chronic pain condition, according research reported in The Journal of Pain, published by the American Pain Society.

1 Dec 2011

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

1 Dec 2011

One-time injection after spinal cord injury can limit pain for 8 months

A collaborative research group - led by researchers at Cleveland Clinic - published findings that indicate a one-time injection immediately after spinal cord injury can limit pain for an extended period of time.

30 Nov 2011

Dramatic nationwide rise in opioid use for chronic abdominal pain

Across U.S. outpatient clinics between 1997 and 2008, opioid prescriptions for chronic abdominal pain more than doubled, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

30 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011